سعر اورينسيا 250مجم بودر للحقن الوريدي 2022

Abatacept 250 mg lyophilized powder for intravenous infusion (Orencia, Bristol-Myers Squibb), a biologic DMARD.

• Moderately to severely active rheumatoid arthritis in adultsPopulation: AdultsDailyMed (US NLM)
• Moderately to severely active polyarticular juvenile idiopathic arthritis (age 2 years and older)Population: Patients 2 years and olderDailyMed (US NLM)
• Active psoriatic arthritis (age 2 years and older)Population: Patients 2 years and olderDailyMed (US NLM)

• Acute infusion-related events were more common than with placebo (9% vs 6%); most frequent were dizziness, headache and hypertension.International label, same product · DailyMed (US NLM)

• The US label lists no contraindications.International label, same product · DailyMed (US NLM)

• Concomitant use with TNF antagonists, other biologic RA/PsA therapy or JAK inhibitors is not recommended (more infections, no added efficacy).International label, same product · DailyMed (US NLM)
• Anaphylaxis and angioedema, including fatal anaphylaxis after the first infusion, have been reported.International label, same product · DailyMed (US NLM)
• Serious infections including sepsis and pneumonia, some fatal; use caution in patients with recurrent or predisposing infections.International label, same product · DailyMed (US NLM)

• Human pregnancy data are insufficient to inform drug-associated risk; no fetal malformations in rat and rabbit studies; consider live-vaccine timing in infants exposed in utero.International label, same product · DailyMed (US NLM)
• No information on presence in human milk; abatacept was present in the milk of lactating rats.International label, same product · DailyMed (US NLM)

• Abatacept: Binds CD80 and CD86 on antigen-presenting cells, blocking their interaction with CD28 and thereby inhibiting full T-cell activation (US label 12.1).